Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results

Stock Track2025-02-28

NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.

The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.

The EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149436505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149436505","market":"us","top_or_hot":-1,"title":"Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results","media":"Stock Track","content":"<p>NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.</p>\n\n<p>The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.</p>\n\n<p>The EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.</p>\n\n<p>The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.</p>\n\n<p>The EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1149436505","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149436505","pubTimestamp":1740754161,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure Ltd. , a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share  fell short of expectations, missing by 20% at a loss of $1.56 per share.The EPS miss appears to have weighed heavily on investor sentiment, as the company'","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"由于2024年全年业绩每股收益未达预期，NovoCure股价暴跌5.3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.\nThe company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.\nThe EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149436505","isCrawlerRequest":true}